Global PROteolysis Targeting Chimera (PROTAC) Sales Market Report 2021

A proteolysis targeting chimera (PROTAC) is a heterobifunctional small molecule composed of two active domains and a linker capable of removing specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.

Market Analysis and Insights: Global PROteolysis Targeting Chimera (PROTAC) Market
The global PROteolysis Targeting Chimera (PROTAC) market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global PROteolysis Targeting Chimera (PROTAC) Scope and Market Size
The global PROteolysis Targeting Chimera (PROTAC) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global PROteolysis Targeting Chimera (PROTAC) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
ARV-110
ARV-471
KYM-001
Others

Segment by Application
Oncology
Others

The PROteolysis Targeting Chimera (PROTAC) market is analysed and market size information is provided by regions (countries). Segment by Application, the PROteolysis Targeting Chimera (PROTAC) market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Arvinas
Kymera
C4 therapeutics
Captor therapeutics
Vividion
Cullgen
Pfizer
Merck
Genentech
AstraZeneca
Amgen
Bayer